Skip to main content

News

NEW TREATMENT OPTION FOR ADULTS WITH ADHD: FOQUEST™ (METHYLPHENIDATE CONTROLLED RELEASE CAPSULES) NOW AVAILABLE IN CANADA

Published on February 1, 2018

First and only methylphenidate product approved in Canada with a 16-hour duration of action PICKERING,…

Read More

BELBUCA® – A NEW TREATMENT OPTION FOR CANADIANS LIVING WITH CHRONIC PAIN – NOW AVAILABLE IN CANADA

Published on January 30, 2018

Pickering, ON (Canada) (January 30, 2018): Purdue Pharma (Canada) and BioDelivery Sciences International Inc. (BDSI)…

Read More

NEW SINGLE CAPSULE TREATMENT AKYNZEO™ NOW AVAILABLE FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN CANADA

Published on November 28, 2017

Pickering, ON (Canada) (November 28, 2017): Purdue Pharma (Canada) announce today that AKYNZEO™ (netupitant/palonosetron hydrochloride)…

Read More

David A. Pidduck Appointed President and CEO of Purdue Pharma (Canada)

Published on September 25, 2017

Pickering, Ontario, September 25, 2017/CNW/ — David A. Pidduck has been appointed as President and…

Read More

ARCHIVE

2018
2017
2016
2015
2014
2013
2012

For all media inquiries, please contact:

media@purdue.ca

↓